CY1117050T1 - CO-OPERATION OF A FACTOR, CONNECTED WITH A TAT Internalisation Peptide, With An Anti-inflammatory Factor - Google Patents
CO-OPERATION OF A FACTOR, CONNECTED WITH A TAT Internalisation Peptide, With An Anti-inflammatory FactorInfo
- Publication number
- CY1117050T1 CY1117050T1 CY20151101108T CY151101108T CY1117050T1 CY 1117050 T1 CY1117050 T1 CY 1117050T1 CY 20151101108 T CY20151101108 T CY 20151101108T CY 151101108 T CY151101108 T CY 151101108T CY 1117050 T1 CY1117050 T1 CY 1117050T1
- Authority
- CY
- Cyprus
- Prior art keywords
- factor
- tat
- inflammatory
- histamine release
- peptide
- Prior art date
Links
Abstract
Η εφεύρεση παρέχει μεθόδους χορήγησης φαρμακολογικών παραγόντων που συνδέονται με ένα πεπτίδιο εσωτερικοποίησης, στις οποίες αναστέλλεται μια φλεγμονώδης ανταπόκριση που προκαλείται από το πεπτίδιο εσωτερικοποίησης με τη συγχορήγηση ενός αντιφλεγμονώδους ή με τη σύνδεση του πεπτιδίου εσωτερικοποίησης με βιοτίνη ή παρόμοιο μόριο. Τέτοιες μέθοδοι προτάσσονται εν μέρει από τα αποτελέσματα που περιγράφονται στα παραδείγματα όπου η χορήγηση ενός φαρμακολογικού παράγονται που συνδέεται με tat σε υψηλές δοσολογίες ακολουθείται στενά από μια φλεγμονώδη ανταπόκριση, που περιλαμβάνει απώλεια των κοκκίων σε μαστοκύτταρα, απελευθέρωση ισταμίνης και το σύνηθες επακόλουθο της απελευθέρωσης ισταμίνης, όπως κοκκίνισμα, έξαψη, πρήξιμο και υπόταση.The invention provides methods of administering pharmacological agents that bind to an internalizing peptide, in which an inflammatory response mediated by the internalizing peptide is inhibited by co-administering an anti-inflammatory or by binding the internalizing peptide to biotin or the like. Such methods are partly supported by the results described in the examples where the administration of a pharmacological derivative associated with tat at high dosages is closely followed by an inflammatory response, including loss of granules in mast cells, histamine release and histamine release, and histamine release. such as redness, flushing, swelling and hypotension.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99267807A | 2007-12-05 | 2007-12-05 | |
EP08859906.3A EP2229185B8 (en) | 2007-12-05 | 2008-12-02 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory agent |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117050T1 true CY1117050T1 (en) | 2017-04-05 |
Family
ID=58487053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151101108T CY1117050T1 (en) | 2007-12-05 | 2015-12-04 | CO-OPERATION OF A FACTOR, CONNECTED WITH A TAT Internalisation Peptide, With An Anti-inflammatory Factor |
Country Status (1)
Country | Link |
---|---|
CY (1) | CY1117050T1 (en) |
-
2015
- 2015-12-04 CY CY20151101108T patent/CY1117050T1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122584T1 (en) | COMBINATION OF A TAT INTERNALIZING PEPTIDE-BINDING FACTOR WITH AN INHIBITOR OF MAST CELL DEGRADATION | |
CY1122674T1 (en) | ANTI-C5A BINDING MOLECULES WITH HIGH BLOCKING ACTIVITY | |
CY1122909T1 (en) | METHODS OF TREATMENT OF EOSINOPHILIC ESEOPHAGITIS BY ADMINISTRATION OF AN IL-4R INHIBITOR | |
CY1124071T1 (en) | FAPMAKOY ANTI-HER3 ANTIBODY CONJUGATE | |
CY1123504T1 (en) | ANTIDOTES FOR FACTOR HA INHIBITORS AND METHODS OF USING THEM | |
CY1124844T1 (en) | PHARMACEUTICAL ANTIBODY PREPARATION | |
CY1123626T1 (en) | HETEROCYCLIC PROTEIN KINASE INHIBITORS | |
CY1120426T1 (en) | ACE2 polypeptide | |
CY1123570T1 (en) | HEPATITIS B NUCLEAR PROTEIN MODIFIERS | |
CY1122556T1 (en) | SUBSTITUTED N-PHENYLPYRIMIDINE-2-AMINE ANALOGS AS AXL KINASE INHIBITORS | |
CY1125274T1 (en) | METHODS OF TREATING CONDITIONS RELATED TO MASP-2-DEPENDENT COMPLEMENT ACTIVATION | |
CY1122720T1 (en) | T CELL RECEPTORS THAT RECOGNIZE RESTRICTED MAGE-A3 MHC CLASS II | |
CY1112215T1 (en) | PIMOVENDANI TO BE USED TO REDUCE HEART SIZE IN Mammals Suffering From Cardiac Deficiency | |
WO2009100194A3 (en) | Camptothecin-binding moiety conjugates | |
CY1119219T1 (en) | ANTI-CEACAM5 ANTIBODIES AND THEIR USES | |
CY1122132T1 (en) | METHODS OF REDUCING ASTHMA FLASH RATE USING BENRALIZUMAB | |
CY1121943T1 (en) | NUCLEOPHILIC CATALYSTS FOR COUPLING OF ACIDS | |
MX2018010247A (en) | Amanitin conjugates. | |
BRPI0821004A8 (en) | AMINOPYRAZOLE DERIVATIVE COMPOUND, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND USE OF IT | |
CY1119954T1 (en) | Oligosaccharides comprising a group of amino acids and their conjugates | |
WO2007112193A3 (en) | Camptothecin-binding moiety conjugates | |
EA201000211A1 (en) | METHOD OF MODELING THE GPR119 RECEPTOR, CONNECTED WITH A G-PROTEIN, AND USED AT THIS CONNECTION | |
MX2019013690A (en) | Cyclodextrin protein drug conjugates. | |
BR112015027322A8 (en) | CONJUGATED ANTI-SENSE COMPOUNDS AND THEIR USE | |
EA201390940A1 (en) | MATERIALS AND METHODS FOR CONJUGATING WATER-SOLUBLE DERIVATIVE FATTY ACID WITH PROTEIN |